Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

European Journal of Cancer

Volumn 47, Issue 11, 2011, Pages 1676-1681

  Pelzer, Uwe ^a   Schwaner, Ingo ^b   Stieler, Jens ^a   Adler, Mathias ^c   Seraphin, Jörg ^d   Dörken, Bernd ^a   Riess, Hanno ^a   Oettle, Helmut ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Outpatient Department   (Germany)

^c Outpatient Department   (Germany)

^d Outpatient Department   (Germany)

Author keywords

Best supportive care; Gemcitabine; Pancreatic cancer; Second line

Indexed keywords

ALIZAPRIDE; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BEST SUPPORTIVE CARE; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; FEMALE; GERMANY; HEALTH CARE DELIVERY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS CANCER; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; GERMANY; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 79960019683     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.04.011     Document Type: Article

References (19)

1. A. Stathis, and M.J. Moore Advanced pancreatic carcinoma: current treatment and future challenges Nat Rev Clin Oncol 7 3 2010 163 172
2. A. Jemal, R. Siegel, and E. Ward Cancer statistics CA Cancer J Clin 59 4 2009 225 249
3. H.A. Burris, M.J. Moore, and J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413 (Pubitemid 27251144)
4. U. Pelzer First-line chemotherapy in advanced pancreatic cancer Recent Results Cancer Res 177 2008 57 60
5. V. Heinemann, P.A. Phillip, and U. Pelzer Accomplishments in 2008 in the treatment of metastatic pancreatic cancer Gastrointest Cancer Res 3 5(Suppl. 2) 2009 S43 S47
6. D. Cunningham, I. Chau, and D.D. Stocken Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 20 33 2009 5513 5518
7. U. Pelzer Second-line chemotherapy in advanced pancreatic cancer Recent Results Cancer Res 177 2008 61 64
8. H. Oettle, D. Arnold, and M. Esser Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma Anticancer Drugs 11 2000 635 638
9. M.H. Kulke, L.S. Blaszkowsky, and D.P. Ryan Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer J Clin Oncol 25 2007 4787 4792 (Pubitemid 350086482)
10. U. Pelzer, J. Stieler, and L. Roll Second-line therapy in refractory pancreatic cancer. Results of a phase ii study Onkologie 32 3 2009 99 102
11. N. Tsavaris, C. Kosmas, and H. Skopelitis Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study Invest New Drugs 23 2005 369 375 (Pubitemid 40980360)
12. A.H. Ko, E. Dito, and B. Schillinger Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study Cancer Invest 26 2008 47 52
13. S. Cereda, and M. Reni Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer J Chemother 20 2008 509 512
14. S. Boeck, K. Weigang-Köhler, and M. Fuchs Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial Ann Oncol 18 2007 745 751 (Pubitemid 46523280)
15. M. Reni, L. Pasetto, and G. Aprile Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer Br J Cancer 94 2006 785 791
16. C. Morizane, T. Okusaka, and J. Furuse A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer Cancer Chemother Pharmacol 63 2009 313 319
17. H.L. Kindler, M. Aklilu, and S. Nattam Arsenic trioxide in patients with adeno-carcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium Am J Clin Oncol 31 2008 553 556
18. M. Ignatiadis, A. Polyzos, and G.P. Stathopoulos A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer Oncology 71 2006 159 163
19. V. Heinemann, S. Boeck, and A. Hinke Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 2008 82